#USA #Immunotherapy #Norwalk #Lifespan Vision #Sift Biosciences

Lifespan Vision Ventures Co-Leads Sift Biosciences' $3.7M Pre-Seed Financing

In a significant boost for innovative healthtech, Lifespan Vision Ventures has announced its co-lead role in a $3.7 million pre-seed funding round for Sift Biosciences. This financing, which saw overwhelming interest, was also supported by Freeflow Ventures and other key players including Valuence Ventures, Eisai Innovation, and the SBI US Gateway Fund.

Sift Biosciences is on the cutting edge of developing a peptide-based immunotherapy platform. Their pioneering work aims to leverage existing immune memory, enhancing immune engagement for a variety of applications. Specifically, their technology focuses on activating pre-existing memory T cells, which have significant implications in oncology and autoimmune diseases.

The company's initial focus includes tackling challenging cases found in 'cold' solid tumors, with colorectal and ovarian cancers at the forefront. Beyond oncology, Sift is also exploring how to control immune responses for therapeutic purposes in immune diseases.

Clare Lou, Ph.D., CEO and co-founder of Sift Biosciences, noted the significance of this funding: "This financing will support in vivo efficacy studies, the expansion of our AI-powered peptide discovery engine, and lead candidate selection." She expressed excitement about the partnership with Lifespan Vision Ventures and the strong syndicate of investors backing their mission.

Altar Munis, Ph.D., an Associate at Lifespan Vision Ventures, highlighted the importance of Sift Biosciences' approach. "We're pleased to support Sift because they are applying clear insights from immunology with a scalable platform. Their system is designed to engage antigen-experienced memory T cells, potentially addressing not just cancer but also autoimmune disorders and the broader immune dysfunctions that can accompany aging."

As part of this investment agreement, Dr. Altar Munis and Freeflow Ventures' Managing Partner Kevin Barrett will step onto Sift Biosciences' Board of Directors, further enriching the company's governance with their expertise.

Lifespan Vision Ventures itself specializes in early-stage biotechnology investments, particularly those targeting age-related diseases. Their mission resonates with the current needs of society to enhance the healthspan, enabling individuals to enjoy longer, healthier lives through groundbreaking scientific solutions. This recent funding is expected to empower Sift Biosciences as they refine their innovative therapies and aim for clinical application.

In the ever-evolving landscape of biotechnology, collaborations like this epitomize the synergy needed between investment and innovation to push the boundaries of what is possible in healthcare. As Sift Biosciences advances its work, the potential benefits for patients suffering from challenging conditions loom large.

The future appears bright for both Lifespan Vision Ventures and Sift Biosciences as they embark on this journey to improve health outcomes and provide new therapeutic options for patients around the globe. With ongoing research efforts and funding, the intersection of finance and health innovation continues to pave the way for future breakthroughs.